Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
Zidavi is recommended by the Infectious Disease Society of America
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
The company to receive upfront and milestone payments, in addition to royalties
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
Subscribe To Our Newsletter & Stay Updated
